Concepts (314)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Weight Loss | 36 | 2022 | 319 | 7.390 |
Why?
|
| Obesity | 49 | 2022 | 1076 | 5.960 |
Why?
|
| Weight Reduction Programs | 10 | 2021 | 67 | 4.780 |
Why?
|
| Overweight | 9 | 2022 | 186 | 2.130 |
Why?
|
| Liraglutide | 5 | 2022 | 18 | 2.100 |
Why?
|
| Diabetes Mellitus, Type 2 | 9 | 2020 | 1085 | 1.830 |
Why?
|
| Hunger | 6 | 2020 | 27 | 1.610 |
Why?
|
| Hypoglycemic Agents | 5 | 2022 | 362 | 1.580 |
Why?
|
| Diet, Reducing | 11 | 2021 | 46 | 1.440 |
Why?
|
| Anti-Obesity Agents | 9 | 2021 | 42 | 1.290 |
Why?
|
| Glucagon-Like Peptides | 3 | 2022 | 15 | 1.030 |
Why?
|
| Body Mass Index | 15 | 2021 | 867 | 1.010 |
Why?
|
| Behavior Therapy | 7 | 2013 | 297 | 0.920 |
Why?
|
| Quality of Life | 6 | 2021 | 1515 | 0.870 |
Why?
|
| Body Weight | 12 | 2022 | 554 | 0.790 |
Why?
|
| Adult | 59 | 2021 | 21403 | 0.780 |
Why?
|
| Blood Glucose | 9 | 2018 | 631 | 0.780 |
Why?
|
| Cardiovascular Diseases | 6 | 2016 | 940 | 0.730 |
Why?
|
| Life Style | 6 | 2017 | 338 | 0.700 |
Why?
|
| Female | 69 | 2022 | 38074 | 0.700 |
Why?
|
| Middle Aged | 45 | 2022 | 21147 | 0.700 |
Why?
|
| Bariatric Surgery | 3 | 2012 | 90 | 0.690 |
Why?
|
| Humans | 82 | 2022 | 68618 | 0.660 |
Why?
|
| Healthy Lifestyle | 1 | 2018 | 21 | 0.640 |
Why?
|
| Male | 54 | 2022 | 37321 | 0.630 |
Why?
|
| Occupational Health | 1 | 2018 | 41 | 0.630 |
Why?
|
| Double-Blind Method | 14 | 2021 | 1738 | 0.620 |
Why?
|
| Neurotoxicity Syndromes | 1 | 2017 | 16 | 0.590 |
Why?
|
| Eating | 4 | 2012 | 119 | 0.580 |
Why?
|
| Obesity, Morbid | 6 | 2017 | 172 | 0.580 |
Why?
|
| Psychosocial Support Systems | 1 | 2017 | 12 | 0.580 |
Why?
|
| Naltrexone | 7 | 2016 | 195 | 0.570 |
Why?
|
| Diabetes Complications | 1 | 2018 | 249 | 0.570 |
Why?
|
| Bulimia | 8 | 2011 | 72 | 0.550 |
Why?
|
| Benzazepines | 3 | 2014 | 104 | 0.530 |
Why?
|
| Bupropion | 4 | 2016 | 63 | 0.500 |
Why?
|
| Education | 1 | 2015 | 83 | 0.490 |
Why?
|
| Feeding Behavior | 6 | 2012 | 224 | 0.480 |
Why?
|
| Problem-Based Learning | 1 | 2015 | 72 | 0.480 |
Why?
|
| Social Control, Informal | 1 | 2013 | 8 | 0.460 |
Why?
|
| Evidence-Based Practice | 1 | 2015 | 146 | 0.450 |
Why?
|
| Patient Care Team | 1 | 2015 | 311 | 0.430 |
Why?
|
| Energy Intake | 4 | 2021 | 123 | 0.420 |
Why?
|
| Behavior Control | 1 | 2012 | 7 | 0.420 |
Why?
|
| Receptor, Serotonin, 5-HT2C | 1 | 2012 | 2 | 0.410 |
Why?
|
| Telemedicine | 2 | 2018 | 700 | 0.410 |
Why?
|
| Social Desirability | 1 | 2011 | 9 | 0.390 |
Why?
|
| Personality Assessment | 1 | 2011 | 71 | 0.380 |
Why?
|
| Interview, Psychological | 1 | 2011 | 113 | 0.380 |
Why?
|
| Diet | 5 | 2018 | 514 | 0.370 |
Why?
|
| Risk Factors | 12 | 2019 | 5731 | 0.370 |
Why?
|
| Aged | 17 | 2020 | 14862 | 0.370 |
Why?
|
| Glucagon-Like Peptide 1 | 2 | 2021 | 17 | 0.350 |
Why?
|
| Cholesterol | 3 | 2016 | 331 | 0.350 |
Why?
|
| Prediabetic State | 3 | 2019 | 48 | 0.350 |
Why?
|
| Dietary Carbohydrates | 2 | 2008 | 27 | 0.340 |
Why?
|
| Bulimia Nervosa | 3 | 2015 | 21 | 0.330 |
Why?
|
| Treatment Outcome | 15 | 2022 | 7029 | 0.320 |
Why?
|
| Triglycerides | 3 | 2016 | 184 | 0.320 |
Why?
|
| Narcotic Antagonists | 4 | 2010 | 184 | 0.310 |
Why?
|
| Cholecalciferol | 2 | 2019 | 143 | 0.300 |
Why?
|
| Heroin Dependence | 2 | 2007 | 23 | 0.300 |
Why?
|
| Program Evaluation | 4 | 2018 | 502 | 0.300 |
Why?
|
| Placebos | 6 | 2022 | 195 | 0.300 |
Why?
|
| Surveys and Questionnaires | 7 | 2017 | 2800 | 0.290 |
Why?
|
| Women | 2 | 2011 | 40 | 0.280 |
Why?
|
| Electronic Mail | 2 | 2017 | 29 | 0.280 |
Why?
|
| Brain | 1 | 2017 | 2176 | 0.280 |
Why?
|
| Cholesterol, HDL | 4 | 2016 | 112 | 0.280 |
Why?
|
| Exercise | 5 | 2022 | 658 | 0.280 |
Why?
|
| Metabolic Syndrome | 1 | 2008 | 191 | 0.280 |
Why?
|
| Telephone | 2 | 2017 | 160 | 0.270 |
Why?
|
| Food Preferences | 4 | 2012 | 46 | 0.260 |
Why?
|
| Pilot Projects | 3 | 2021 | 1342 | 0.260 |
Why?
|
| Injections, Subcutaneous | 3 | 2022 | 87 | 0.260 |
Why?
|
| Psychotherapy | 1 | 2008 | 253 | 0.260 |
Why?
|
| Research Design | 2 | 2008 | 729 | 0.250 |
Why?
|
| Combined Modality Therapy | 4 | 2021 | 951 | 0.240 |
Why?
|
| Adolescent | 13 | 2017 | 8912 | 0.220 |
Why?
|
| Waist Circumference | 2 | 2016 | 32 | 0.220 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2008 | 504 | 0.220 |
Why?
|
| Body Composition | 2 | 2008 | 119 | 0.210 |
Why?
|
| Diet Records | 2 | 2001 | 14 | 0.210 |
Why?
|
| Young Adult | 8 | 2017 | 5717 | 0.210 |
Why?
|
| Counseling | 2 | 2016 | 280 | 0.210 |
Why?
|
| Body Constitution | 2 | 2002 | 24 | 0.200 |
Why?
|
| Blood Pressure | 3 | 2016 | 1451 | 0.200 |
Why?
|
| Follow-Up Studies | 3 | 2016 | 3259 | 0.200 |
Why?
|
| Prospective Studies | 3 | 2020 | 3705 | 0.190 |
Why?
|
| Hyperphagia | 1 | 2000 | 7 | 0.190 |
Why?
|
| Sensitivity and Specificity | 3 | 2016 | 1753 | 0.180 |
Why?
|
| Goals | 1 | 2000 | 65 | 0.180 |
Why?
|
| Mental Disorders | 4 | 2017 | 659 | 0.180 |
Why?
|
| Retrospective Studies | 6 | 2018 | 7277 | 0.170 |
Why?
|
| Dietary Supplements | 2 | 2019 | 332 | 0.170 |
Why?
|
| Gastric Bypass | 2 | 2013 | 83 | 0.170 |
Why?
|
| Sulfonylurea Compounds | 1 | 2018 | 17 | 0.160 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 1 | 2018 | 14 | 0.160 |
Why?
|
| Metformin | 1 | 2018 | 63 | 0.160 |
Why?
|
| Vitamins | 1 | 2019 | 134 | 0.160 |
Why?
|
| Workplace | 1 | 2018 | 75 | 0.160 |
Why?
|
| Videoconferencing | 1 | 2018 | 43 | 0.160 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2017 | 58 | 0.150 |
Why?
|
| Attitude to Health | 1 | 2000 | 403 | 0.150 |
Why?
|
| Mortality | 1 | 1998 | 163 | 0.150 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2017 | 1745 | 0.150 |
Why?
|
| Rural Health Services | 1 | 2018 | 101 | 0.140 |
Why?
|
| Vitamin D | 2 | 2019 | 516 | 0.140 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2017 | 84 | 0.140 |
Why?
|
| Motivation | 2 | 2018 | 561 | 0.140 |
Why?
|
| Adipose Tissue | 2 | 1997 | 221 | 0.140 |
Why?
|
| Feeding and Eating Disorders | 2 | 2012 | 106 | 0.140 |
Why?
|
| Comorbidity | 4 | 2016 | 1426 | 0.140 |
Why?
|
| Crime Victims | 2 | 2015 | 286 | 0.140 |
Why?
|
| United States | 7 | 2022 | 7367 | 0.140 |
Why?
|
| Appetite Regulation | 2 | 2006 | 11 | 0.140 |
Why?
|
| Health Behavior | 1 | 2020 | 458 | 0.130 |
Why?
|
| Fasting | 2 | 2013 | 75 | 0.130 |
Why?
|
| C-Reactive Protein | 1 | 2016 | 180 | 0.130 |
Why?
|
| Cholesterol, LDL | 1 | 2016 | 161 | 0.130 |
Why?
|
| Patient Selection | 3 | 2011 | 592 | 0.130 |
Why?
|
| Neuropsychological Tests | 2 | 2017 | 517 | 0.130 |
Why?
|
| Psychiatric Status Rating Scales | 4 | 2011 | 782 | 0.130 |
Why?
|
| Delayed-Action Preparations | 3 | 2010 | 120 | 0.130 |
Why?
|
| Stress Disorders, Post-Traumatic | 2 | 2015 | 1506 | 0.130 |
Why?
|
| Hyperglycemia | 1 | 2017 | 158 | 0.130 |
Why?
|
| Rural Population | 1 | 2018 | 398 | 0.120 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2017 | 931 | 0.120 |
Why?
|
| Mental Health | 1 | 2017 | 278 | 0.120 |
Why?
|
| Binge-Eating Disorder | 1 | 2014 | 16 | 0.120 |
Why?
|
| Health Education | 1 | 2016 | 279 | 0.120 |
Why?
|
| Patient Education as Topic | 1 | 2017 | 425 | 0.120 |
Why?
|
| Disease Management | 1 | 2015 | 248 | 0.110 |
Why?
|
| Drug Administration Schedule | 3 | 2022 | 567 | 0.110 |
Why?
|
| Students, Medical | 1 | 2015 | 210 | 0.110 |
Why?
|
| Executive Function | 1 | 2013 | 106 | 0.110 |
Why?
|
| Heart Failure | 1 | 2021 | 1180 | 0.110 |
Why?
|
| Adiposity | 1 | 2013 | 88 | 0.100 |
Why?
|
| Seasons | 2 | 2011 | 129 | 0.100 |
Why?
|
| Nerve Net | 1 | 2013 | 181 | 0.100 |
Why?
|
| Self Care | 2 | 2005 | 253 | 0.100 |
Why?
|
| Parturition | 1 | 2011 | 15 | 0.100 |
Why?
|
| Curriculum | 1 | 2015 | 575 | 0.090 |
Why?
|
| Biomarkers | 1 | 2016 | 1593 | 0.090 |
Why?
|
| Food | 1 | 2011 | 52 | 0.090 |
Why?
|
| Vomiting | 1 | 2011 | 56 | 0.090 |
Why?
|
| Risk Reduction Behavior | 1 | 2012 | 174 | 0.090 |
Why?
|
| Preoperative Care | 1 | 2011 | 275 | 0.080 |
Why?
|
| Caloric Restriction | 2 | 2007 | 22 | 0.080 |
Why?
|
| Echocardiography | 1 | 2012 | 515 | 0.080 |
Why?
|
| Psychometrics | 1 | 2011 | 514 | 0.080 |
Why?
|
| Remission Induction | 1 | 2008 | 111 | 0.080 |
Why?
|
| Health Planning Guidelines | 1 | 2008 | 23 | 0.080 |
Why?
|
| Observation | 1 | 2008 | 30 | 0.080 |
Why?
|
| Cross-Sectional Studies | 3 | 2017 | 2279 | 0.070 |
Why?
|
| Receptors, Neuropeptide Y | 1 | 2007 | 5 | 0.070 |
Why?
|
| Cyclohexanes | 1 | 2007 | 10 | 0.070 |
Why?
|
| Spiro Compounds | 1 | 2007 | 14 | 0.070 |
Why?
|
| Drug Therapy, Combination | 3 | 2016 | 649 | 0.070 |
Why?
|
| Depression | 3 | 2006 | 943 | 0.070 |
Why?
|
| Exercise Therapy | 1 | 2008 | 183 | 0.070 |
Why?
|
| Transcranial Magnetic Stimulation | 1 | 2011 | 413 | 0.070 |
Why?
|
| Vagus Nerve | 1 | 2006 | 90 | 0.070 |
Why?
|
| Pyrazoles | 1 | 2007 | 190 | 0.070 |
Why?
|
| Prefrontal Cortex | 1 | 2011 | 640 | 0.060 |
Why?
|
| Electric Stimulation Therapy | 1 | 2006 | 147 | 0.060 |
Why?
|
| Logistic Models | 1 | 2008 | 1420 | 0.060 |
Why?
|
| Drug Implants | 1 | 2004 | 19 | 0.060 |
Why?
|
| Diabetes Mellitus | 2 | 2022 | 694 | 0.060 |
Why?
|
| Body Image | 2 | 1997 | 100 | 0.060 |
Why?
|
| Patient Dropouts | 2 | 2022 | 98 | 0.060 |
Why?
|
| Relaxation Therapy | 1 | 2003 | 19 | 0.060 |
Why?
|
| Administration, Oral | 2 | 2019 | 411 | 0.050 |
Why?
|
| Pulse | 1 | 2002 | 23 | 0.050 |
Why?
|
| Patient Compliance | 2 | 2003 | 402 | 0.050 |
Why?
|
| Analysis of Variance | 2 | 2006 | 1040 | 0.050 |
Why?
|
| Health Surveys | 2 | 2011 | 489 | 0.050 |
Why?
|
| Diet Therapy | 1 | 2022 | 22 | 0.050 |
Why?
|
| Prevalence | 4 | 2005 | 1619 | 0.050 |
Why?
|
| Reproducibility of Results | 2 | 2005 | 2077 | 0.050 |
Why?
|
| Exercise Tolerance | 1 | 2021 | 75 | 0.050 |
Why?
|
| Cognition | 2 | 1999 | 513 | 0.050 |
Why?
|
| Hospitalization | 1 | 2007 | 978 | 0.050 |
Why?
|
| Sampling Studies | 1 | 2000 | 80 | 0.050 |
Why?
|
| South Carolina | 3 | 2018 | 2752 | 0.050 |
Why?
|
| Holidays | 1 | 2000 | 3 | 0.040 |
Why?
|
| Parenteral Nutrition, Total | 1 | 1980 | 22 | 0.040 |
Why?
|
| Depressive Disorder, Major | 2 | 2015 | 439 | 0.040 |
Why?
|
| Christianity | 1 | 2000 | 16 | 0.040 |
Why?
|
| Parenteral Nutrition | 1 | 1980 | 39 | 0.040 |
Why?
|
| Odds Ratio | 1 | 2022 | 880 | 0.040 |
Why?
|
| Lipase | 1 | 1999 | 16 | 0.040 |
Why?
|
| Incidence | 2 | 2018 | 1603 | 0.040 |
Why?
|
| Weight Gain | 1 | 2000 | 135 | 0.040 |
Why?
|
| Lactones | 1 | 1999 | 64 | 0.040 |
Why?
|
| Age Factors | 2 | 2000 | 1864 | 0.040 |
Why?
|
| Stroke Volume | 1 | 2021 | 586 | 0.040 |
Why?
|
| Treatment Failure | 1 | 2019 | 216 | 0.040 |
Why?
|
| Disease-Free Survival | 1 | 2019 | 349 | 0.040 |
Why?
|
| Antidepressive Agents | 2 | 2010 | 216 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2019 | 536 | 0.040 |
Why?
|
| Cohort Studies | 2 | 2018 | 2358 | 0.040 |
Why?
|
| Educational Status | 1 | 1998 | 273 | 0.040 |
Why?
|
| Cerebrovascular Disorders | 1 | 1998 | 182 | 0.040 |
Why?
|
| Age of Onset | 2 | 2014 | 188 | 0.040 |
Why?
|
| Buttocks | 1 | 1997 | 16 | 0.040 |
Why?
|
| Thigh | 1 | 1997 | 27 | 0.040 |
Why?
|
| Smoking | 1 | 2005 | 1452 | 0.040 |
Why?
|
| Affect | 2 | 2003 | 218 | 0.040 |
Why?
|
| Risk | 1 | 1998 | 563 | 0.040 |
Why?
|
| Respiratory System | 1 | 2016 | 28 | 0.040 |
Why?
|
| Abdomen | 1 | 1997 | 80 | 0.040 |
Why?
|
| Endpoint Determination | 1 | 2016 | 82 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2000 | 1553 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 1998 | 792 | 0.030 |
Why?
|
| Enzyme Inhibitors | 1 | 1999 | 659 | 0.030 |
Why?
|
| Cardiovascular System | 1 | 2016 | 85 | 0.030 |
Why?
|
| Ovarian Neoplasms | 1 | 1997 | 267 | 0.030 |
Why?
|
| Health Promotion | 1 | 2000 | 407 | 0.030 |
Why?
|
| Clinical Trials as Topic | 2 | 1998 | 848 | 0.030 |
Why?
|
| Sleep Apnea Syndromes | 1 | 1995 | 40 | 0.030 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 1997 | 245 | 0.030 |
Why?
|
| Sex Offenses | 1 | 1997 | 170 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 1997 | 468 | 0.030 |
Why?
|
| Taste | 2 | 2008 | 49 | 0.030 |
Why?
|
| Dietary Fats | 2 | 2008 | 103 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2014 | 238 | 0.030 |
Why?
|
| Interviews as Topic | 1 | 2015 | 392 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2018 | 1330 | 0.030 |
Why?
|
| Phentermine | 1 | 2013 | 17 | 0.030 |
Why?
|
| Patient Acceptance of Health Care | 1 | 1997 | 468 | 0.030 |
Why?
|
| Postoperative Period | 1 | 2013 | 238 | 0.030 |
Why?
|
| Fructose | 1 | 2013 | 51 | 0.030 |
Why?
|
| Desipramine | 1 | 1993 | 47 | 0.030 |
Why?
|
| Primary Health Care | 1 | 2018 | 703 | 0.030 |
Why?
|
| Cognition Disorders | 1 | 1995 | 342 | 0.030 |
Why?
|
| Aged, 80 and over | 2 | 2018 | 4848 | 0.030 |
Why?
|
| Reference Values | 2 | 2011 | 579 | 0.030 |
Why?
|
| Panic Disorder | 1 | 1993 | 121 | 0.030 |
Why?
|
| Social Environment | 1 | 2013 | 182 | 0.020 |
Why?
|
| Neurotransmitter Agents | 2 | 2007 | 102 | 0.020 |
Why?
|
| Sex Factors | 3 | 2004 | 1266 | 0.020 |
Why?
|
| Cross-Over Studies | 1 | 2011 | 260 | 0.020 |
Why?
|
| Photic Stimulation | 1 | 2011 | 229 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2010 | 129 | 0.020 |
Why?
|
| Biogenic Monoamines | 1 | 1990 | 18 | 0.020 |
Why?
|
| Depressive Disorder | 2 | 1995 | 621 | 0.020 |
Why?
|
| Drug Combinations | 1 | 2010 | 304 | 0.020 |
Why?
|
| Mice, Obese | 1 | 2008 | 33 | 0.020 |
Why?
|
| Animal Feed | 1 | 2008 | 52 | 0.020 |
Why?
|
| Prognosis | 1 | 2013 | 2093 | 0.020 |
Why?
|
| Substance-Related Disorders | 2 | 2014 | 1242 | 0.020 |
Why?
|
| Tryptophan | 1 | 1988 | 65 | 0.020 |
Why?
|
| Western Australia | 1 | 2007 | 4 | 0.020 |
Why?
|
| Neoplasms | 1 | 1998 | 1667 | 0.020 |
Why?
|
| Medical Record Linkage | 1 | 2007 | 42 | 0.020 |
Why?
|
| Alcoholism | 1 | 2015 | 1109 | 0.020 |
Why?
|
| Time Factors | 2 | 2006 | 4655 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2013 | 3187 | 0.020 |
Why?
|
| Mood Disorders | 1 | 1987 | 132 | 0.020 |
Why?
|
| Contraindications | 1 | 2005 | 52 | 0.020 |
Why?
|
| Psychotropic Drugs | 1 | 2005 | 83 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2013 | 2223 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2006 | 546 | 0.010 |
Why?
|
| Program Development | 1 | 2005 | 240 | 0.010 |
Why?
|
| Appetite | 1 | 2003 | 16 | 0.010 |
Why?
|
| Self Concept | 1 | 2004 | 132 | 0.010 |
Why?
|
| Affective Symptoms | 1 | 2003 | 50 | 0.010 |
Why?
|
| Syndrome | 1 | 2003 | 255 | 0.010 |
Why?
|
| Sexual Behavior | 1 | 2004 | 183 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2004 | 737 | 0.010 |
Why?
|
| Child | 1 | 2013 | 6405 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2008 | 2550 | 0.010 |
Why?
|
| Economics, Nursing | 1 | 1980 | 2 | 0.010 |
Why?
|
| Convalescence | 1 | 1980 | 11 | 0.010 |
Why?
|
| Anxiety | 1 | 2003 | 422 | 0.010 |
Why?
|
| Physical Exertion | 1 | 2000 | 75 | 0.010 |
Why?
|
| Mass Screening | 1 | 2005 | 843 | 0.010 |
Why?
|
| Community Health Services | 1 | 2000 | 141 | 0.010 |
Why?
|
| Acute Disease | 1 | 1980 | 658 | 0.010 |
Why?
|
| Carboplatin | 1 | 1997 | 59 | 0.010 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 1997 | 57 | 0.010 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 1997 | 88 | 0.010 |
Why?
|
| Cyclophosphamide | 1 | 1997 | 129 | 0.010 |
Why?
|
| Paclitaxel | 1 | 1997 | 140 | 0.010 |
Why?
|
| Stress, Psychological | 1 | 2003 | 824 | 0.010 |
Why?
|
| Family | 1 | 1979 | 293 | 0.010 |
Why?
|
| Mice | 1 | 2008 | 8474 | 0.010 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 1 | 1997 | 257 | 0.010 |
Why?
|
| Wechsler Scales | 1 | 1995 | 15 | 0.010 |
Why?
|
| Polysomnography | 1 | 1995 | 92 | 0.010 |
Why?
|
| Phobic Disorders | 1 | 1995 | 227 | 0.010 |
Why?
|
| Anxiety Disorders | 1 | 1995 | 426 | 0.010 |
Why?
|
| Animals | 1 | 2008 | 20881 | 0.010 |
Why?
|
| Hydroxyindoleacetic Acid | 1 | 1990 | 36 | 0.010 |
Why?
|
| Homovanillic Acid | 1 | 1990 | 52 | 0.010 |
Why?
|
| Thinking | 1 | 1989 | 30 | 0.010 |
Why?
|
| Internal-External Control | 1 | 1989 | 60 | 0.010 |
Why?
|
| Norepinephrine | 1 | 1990 | 276 | 0.010 |
Why?
|
| Attitude | 1 | 1989 | 121 | 0.010 |
Why?
|
| Appetite Depressants | 1 | 1988 | 11 | 0.000 |
Why?
|
| Stomach | 1 | 1988 | 80 | 0.000 |
Why?
|
| Serotonin | 1 | 1988 | 144 | 0.000 |
Why?
|
| Prostheses and Implants | 1 | 1988 | 159 | 0.000 |
Why?
|
| Transaminases | 1 | 1985 | 21 | 0.000 |
Why?
|
| Random Allocation | 1 | 1985 | 442 | 0.000 |
Why?
|
| Taste Threshold | 1 | 1980 | 2 | 0.000 |
Why?
|
| Hydrochloric Acid | 1 | 1980 | 19 | 0.000 |
Why?
|
| Osmolar Concentration | 1 | 1980 | 134 | 0.000 |
Why?
|
| Urea | 1 | 1980 | 51 | 0.000 |
Why?
|
| Sucrose | 1 | 1980 | 58 | 0.000 |
Why?
|
| Sodium Chloride | 1 | 1980 | 136 | 0.000 |
Why?
|
| Liver | 1 | 1985 | 1118 | 0.000 |
Why?
|
| Aging | 1 | 1980 | 911 | 0.000 |
Why?
|